- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02124577
Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD
Development of Kinetic Biomarkers of Liver Fibrosis Based on Stable Isotope Mass Spectrometry Techniques for Measuring Nonalcoholic Fatty Liver Disease NAFLD)
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Management of NASH and NAFLD remain a significant unmet medical challenge that is growing in importance as part of the obesity epidemic. Minimally invasive tools for monitoring disease progression and evaluating therapeutic interventions in NASH would be extremely valuable. Utilizing in vivo heavy water labeling, multiple pathways related to protein metabolism (fibrogenesis) and lipid metabolism can be quantified in human subjects. We have recently discovered that plasma lumicam synthesis represents a non-invasive kinetic biomarker of tissue fibrogenesis in patients with viral hepatitis. In addition, synthesis of fatty acids in plasma VLDL-triglycerides provide a window into hepatic lipid metabolism.
Stable isotopes have a long history as a safe, effective tracer for measuring synthesis of molecules in humans (1). Recently, new developments in stable isotope labeling techniques and advances in mass spectrometry have made in vivo kinetic measurement of slow metabolic processes possible. Through the use of 2H2O as the source of labeling, we and others have measured T-cell proliferation (2), mammary epithelial cell proliferation (3), prostate epithelial cell proliferation (4), triglyceride synthesis (5) and protein synthesis (6) in humans. We have recently evaluated this approach for the measurement of fibrogenesis patients with fibrotic liver disease.
Excess accumulation of collagen in the liver is termed fibrosis. Fibrosis is a common pathological feature of several chronic liver diseases (e.g. Hepatitis C, alcoholic liver disease, primary biliary sclerosis, drug/toxin induced liver disease, etc.). Currently, the standard method for detection of fibrosis is liver biopsy and histochemical analyses of tissue collagen content (8, 9). Although effective in diagnosing existing, advanced fibrosis, a single biopsy cannot measure current disease activity or predict rate of progression. To determine whether disease is progressing using current methods, a second biopsy is required. If significant additional collagen has accumulated since the first biopsy, this suggests that the disease is progressing. However, this measurement represents the history of the disease, not the current disease activity at the time of the second biopsy. There are also significant limitations in current methods, since changes in collagen pool size measurable by histochemistry cannot measure small changes in collagen content and intra-laboratory variability inherent in histochemical assays reduce their sensitivity (10, 11).
This stable isotope / mass spectrometry based method will be applied here for the quantification of fibrogenesis in vivo (from a bone marrow biopsy) and the identification of novel biomarkers of fibrogenesis in plasma in patients receiving investigational therapies.
If successful, this research will identify plasma proteins which can be easily measured by tandem mass spectrometry (LC/MS/MS) methods and whose synthesis rate reflects disease activity in the heart. Ideally, a set of markers related to NASH/ NAFLD will be developed that can detect and differentiate among multiple disease phenotypes, based on the kinetic signature measured in a single blood draw from a patient labeled with deuterated water.
The role of de novo lipogenesis (DNL) has been suggested by several clinical studies (Donnelly JCI 2005, Puri Hepatology 2009). DNL contributes significantly to the accumulation of lipid in NASH (Donnelly JCI 2005). Moreover DNL is elevated in many other inflammatory states and may be a useful marker of hepatic inflammation. DNL as well as hepatic TG assembly and cholesterogenesis are easily measured in plasma or dried blood spot samples from patients consuming 2H2O, after several days of labeling the plasma DNL reaches a steady state and reflects hepatic DNL rates.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Leander A Lazaro
- Numero di telefono: 619-471-3915
- Email: llazaro@ucsd.edu
Backup dei contatti dello studio
- Nome: Phirum Nguyen
- Numero di telefono: 619-471-0774
- Email: psnguyen@ucsd.edu
Luoghi di studio
-
-
California
-
San Diego, California, Stati Uniti, 92103
- Reclutamento
- University of California, San Diego
-
Contatto:
- Leander A Lazaro
- Numero di telefono: 619-471-3915
-
Contatto:
- Phirum S. Nguyen
- Numero di telefono: 619-471-0774
- Email: psnguyen@ucsd.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Adults (≥ 18 years of age)
- Adult male and female subjects, all races, ethnic groups, social and economic backgrounds and health status who are scheduled to undergo a liver biopsy as part of routine medical care will be included in the research.
- Willingness to follow-up for 8 weeks
- Written inform consent.
Exclusion Criteria:
- Children younger than 18 will be excluded, since growth of liver tissue may confound measurements of collagen synthesis and cell proliferation due to normal turnover or disease.
- The eligibility of patients will be determined by Dr. Rohit Loomba, MD or a referring physician at the time the potential subject is recommended to undergo a liver biopsy procedure as part of their medical treatment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
evaluate stable isotope/mass spectrometric methods
Lasso di tempo: Baseline
|
Our primary aim is to evaluate stable isotope/mass spectrometric methods for measuring in vivo liver collagen synthesis (fibrogenesis) and liver lipogenesis rates using liver biopsy specimens from patients with Non-Alcoholic Steatohepatitis (NASH)/ Nonalcoholic fatty liver disease (NAFLD).
|
Baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
serum or urine markers of liver fibrogenesis that can be measured by the same stable isotope/mass spectrometric approach
Lasso di tempo: Baseline
|
Our secondary aim is to look for new serum or urine markers of liver fibrogenesis that can be measured by the same stable isotope/mass spectrometric approach in the same subjects.
Subjects will drink the safe, non-toxic stable isotope heavy water (2H2O, deuterated water) prior to having a liver biopsy and providing urine and blood samples.
|
Baseline
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Rohit Loomba, MD, University of California, San Diego
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 140338
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .